BioSpace News Archive

Drug Development

Biopharma Update on the Novel Coronavirus: March 30

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.

March 30, 2020
·
5 min read
·
BioSpace Editorial Staff
Drug Development

Cobra Bio Secures $3.3 Million to Develop DNA Vaccine Against COVID-19

Cobra Biologics and the Karolinska Institutet, secured millions in emergency funding from Horizon 2020 to support research and development and an eventual Phase I clinical trial testing of a DNA vaccine against COVID-19.

March 30, 2020
·
2 min read
·
Alex Keown
Pharm Country

J&J Identifies Lead COVID-19 Vaccine Candidate, Commits to Supply 1 Billion Vaccines Worldwide

The healthcare giant said it selected a lead vaccine candidate and plans to begin human testing in September, with first batches available under potential emergency use authorization in the first part of 2021.

March 30, 2020
·
2 min read
·
Alex Keown
Business

CRISPR Pioneer Jennifer Doudna Expects Automated COVID-19 Test Lab to Begin Testing Next Week

Doudna announced she is converting a 2,500-square-foot scientific lab at Berkeley’s Innovative Genomics Institute into a lab for testing for the novel coronavirus that causes COVID-19.

March 30, 2020
·
3 min read
·
Mark Terry
Business

Immune Regulation Ltd Appoints Jonathan Rigby as Chief Executive Officer

Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases

March 30, 2020
·
3 min read
FDA

Amidst Controversy, FDA Issues EUA Allowing Anti-Malaria Drugs to Be Used to Treat COVID-19

Scientists and physicians have been cautious about use of the drug for the disease, while President Trump touted it as a “game changer.”

March 30, 2020
·
4 min read
·
Mark Terry
Business

GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy

First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.

March 30, 2020
·
4 min read
·
Gail Dutton
Drug Development

AstraZeneca’s Farxiga Shows ‘Overwhelming Efficacy’ in Phase III CKD Trial

AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease.

March 30, 2020
·
2 min read
·
Alex Keown
Heidelberg Pharma Publishes Article on Chemical Amanitin Synthesis in Angewandte Chemie Journal

Heidelberg Pharma AG announced that a scientific article on the chemical synthesis of the fungal compound Amanitin has been published in Angewandte Chemie, a leading chemical journal.

March 30, 2020
·
4 min read
Drug Development

Biohaven Preps to Submit Expanded Label for Nurtec Following Positive Migraine Trial Results

Biohaven Pharmaceutical announced positive topline data from its Phase III trial of oral rimegepant (Nurtec) for preventing migraine headaches in both episodic and chronic migraine patients.

March 30, 2020
·
3 min read
·
Mark Terry